GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.
The ZOE-70 study in 14,800 adults aged 70 years and over met its primary objective, demonstrating 90% (95% confidence interval:...






